TrialBreast cancer research : BCR2025

Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2- advanced or metastatic breast cancer: phase 1/2 study results.

Erika P Hamilton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.